Projekt

A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension (PAH)

Abgebrochen · 2012 bis 2014

Burger Barbara, Haider Karin, Brutsche Martin